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IMPORTANCE Reductions in sugar-sweetened beverage (SSB) intake can improve health, but
are difficult for individuals to achieve on their own.
OBJECTIVES To evaluate whether a workplace SSB sales ban was associated with SSB intake
and cardiometabolic health among employees and whether a brief motivational intervention
provides added benefits to the sales ban.
DESIGN, SETTING, AND PARTICIPANTS This before-after study and additional randomized trial
conducted from July 28, 2015, to October 16, 2016, at a Northern California university and
hospital assessed SSB intake, anthropometrics, and cardiometabolic biomarkers among
214 full-time English-speaking employees whowere frequent SSB consumers (360mL
[12 fl oz] per day) before and 10months after implementation of an SSB sales ban in a large
workplace, with half the employees randomized to receive a brief motivational intervention
targeting SSB reduction.
INTERVENTIONS The employer stopped selling SSBs in all workplace venues, and half the
sample was randomized to receive a brief motivational intervention and the other half was a
control group that did not receive the intervention. This intervention wasmodeled on
standard brief motivational interventions for alcohol used in the workplace that promote
health knowledge and goal setting.
MAIN OUTCOMES ANDMEASURES Outcomes included changes in SSB intake, Homeostatic
Model Assessment of Insulin Resistance (HOMA-IR), andmeasures of abdominal adiposity.
The primary associations tested were the correlation between changes in SSB intake and
changes in HOMA-IR.
RESULTS Among the 214 study participants, 124 (57.9%) were women, with a mean (SD) age
of 41.2 (11.0) years and a baseline mean (SD) bodymass index of 29.4 (6.5). They reported
amean daily intake of 1050mL (35 fl oz) of SSBs at baseline and 540mL (18 fl oz) at
follow-up—a 510-mL (17–fl oz) (48.6%) decrease (P < .001). Reductions in SSB intake
correlated with improvements in HOMA-IR (r = 0.16; P = .03). Those not randomized to
receive the brief intervention reduced their SSB intake by amean (SD) of 246.0 (84.0) mL
(8.2 [2.8] fl oz), while those also receiving the brief intervention reduced SSB intake by
762.0 (84.0) mL (25.4 [2.8] fl oz). From baseline to follow-up, there were significant
reductions in mean (SE) waist circumference (2.1 [2.8] cm; P < .001).
CONCLUSIONS AND RELEVANCE This study’s findings suggest that the workplace sales banwas
associated with a reduction in SSB intake and a significant reduction in waist circumference
among employees within 10months. The randomized clinical trial portion of this study found
that targeting those at high risk with a brief motivational intervention led to additional
improvements. Workplace sales bans may offer a promising new private-sector strategy for
reducing the health harms of SSB intake.
TRIAL REGISTRATION ClinicalTrials.gov identifier: NCT02585336
JAMA Intern Med. doi:10.1001/jamainternmed.2019.4434
Published online October 28, 2019.
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S ugar-sweetened beverage (SSB) intake has emerged asan important risk factor for obesity and cardiometa-bolic disease, and is implicated in 180000 deaths per
year globally.1 Sugar-sweetened beverages (defined as sodas,
sports or energydrinks, “fruit” drinks, and sweetenedbottled
teas and coffees) account for 34% of the added sugar in the
American diet.2 Socioeconomically disadvantaged popula-
tions consume disproportionately more SSBs.3 Meta-
analyses report that SSBs confer greater risk for adversemeta-
bolic health outcomes than do equivalent amounts of added
sugar in foods.4,5 In 2015, the US Dietary Guidelines Added
Sugars Subcommittee recommended that Americans reduce
SSB intake to prevent obesity and type 2 diabetes.6
Health systems, schools, and private employers have be-
gun to discourage SSB intake through modifications in the
workplace food environment that nudge consumers toward
healthier beverage options.7 However, simply promoting
healthy products without removing unhealthy, hyperpalat-
able alternatives from the environment may dampen health
outcomes, particularly for individuals challenged by hedonic
drives to consume sugar.8,9
Private employers have begun to ban the sale of SSBs in
their cafeterias and vendingmachines. Health sector institu-
tions, including the Cleveland Clinic, University of Michigan
HealthSystem,BaylorHealthCareSystem,andGeisingerClinic,
have led thedeploymentof institutionalSSBsalesbans.10,11The
HealthierHospital Initiative, comprisingmorethan500UShos-
pitals, promoteshealthybeveragepolicies, includingSSBsales
bans.12 In2018, theNationalHealthServiceof theUnitedKing-
domstopped selling SSBs inhospitals throughoutEngland. So
far, to our knowledge, no peer-reviewed studies have exam-
ined the association of this approach with employee health.
In2015, theUniversityofCaliforniaatSanFrancisco (UCSF)
implementedacomprehensiveworkplace salesban that elimi-
natedSSBsalesacrossallcampusandmedicalcentervenues.We
evaluated the sales ban’s associationwith SSB intake, abdomi-
naladiposity,and insulinsensitivity inUCSFemployeeswhore-
ported heavy SSB intake (≥360mL [≥12 fl oz] per day) prior to
implementationofthesalesban.Beforethe implementation,we
randomizedhalf thestudyparticipantstoalsoreceiveabriefmo-
tivational interventiontargetingreductions inSSBintake.Wehy-
pothesizedthatasalesbanwouldbeassociatedwithreducedSSB
intake,abdominaladiposity, and insulin resistance, andthat re-
ductions inSSB intakewouldbeassociatedwith improvements
in insulinsensitivity, and, secondarily, abdominaladiposity.We
also hypothesized that participantswho received a briefmoti-
vational intervention in a randomized trial, modeled on com-
monly used workplace interventions for alcohol, would show
greater improvements in SSB intake compared with a control
group that did not receive this intervention.
Methods
On November 1, 2015, the UCSF Healthy Beverage Initiative
eliminated the sale of SSBs in all UCSF venues, including caf-
eterias, vending machines, hospital food services, and retail
outlets.Employees, students, andvisitors couldstill drinkSSBs
on campus if they brought them into university buildings or
grounds. The study took place at one of the UCSFmain cam-
puses that had a clinical research center. The Committee on
Human Research at UCSF approved all study procedures and
allparticipantsprovidedwritten informedconsentprior topar-
ticipation. We assured participants that their survey re-
sponses would not be shared with their supervisors or asso-
ciated with any university records.
Procedures and Recruitment
For an approximately 2-month period preceding the SSB sales
ban (July 28 to October 1, 2015), we surveyed a representative
sample of 2556 employees about their daily patterns of bever-
age intake (including SSBs and non-SSBs), and all participants
completedabaselineassessmentbefore implementationof the
salesban.Lower-incomeserviceandmanualworkerswereover-
sampled because of their higher intake of SSBs and increased
risk of cardiometabolic diseases. Employees completed either
an online Qualtrics survey or paper questionnaire, offered in
English, Spanish, and Chinese (depending on the participant’s
preference). Participants received a $25 gift card. Identical re-
peated surveys were performed at 6 and 12months.
The baseline survey identified high-risk employees with
heavy SSB intake for this study. Inclusion criteria were:
(1) drinking at least 360mL (12 fl oz) of SSBs daily for the past
3months; (2) full-timeemployment atUCSF, at the samecam-
pus where the study took place; (3) ability to fast for phle-
botomy; and (4) having no definitive plans to leave UCSF. Ex-
clusion criteria included: not speaking English, having type 1
or type 2 diabetes, being unwilling or medically advised not
to fast forphlebotomy, reportingavasovagal response tophle-
botomy, being pregnant or nursing, or regularly working the
night shift. Night shift workers may have stronger motiva-
tions to drink SSBs to stay alert, and are more vulnerable to
metabolic dysregulation.13
We screened 699 survey participants who reported drink-
ing 360mL ormore (≥12 fl oz) of SSBs per day for potential eli-
gibility, interest, and ability to participate given their sched-
ules and campus locations (Figure 1). Two months prior to
implementationof theSSBsalesban,we screenedparticipants
by telephone, email, and in person. We successfully recruited
Key Points
Question Was a workplace sales ban on sugar-sweetened
beverages (SSBs) associated with a reduction in employee intake
of sugar-sweetened beverages and improvement in their
cardiometabolic health?
Findings In this before-after study and trial that included 214
adults who regularly drank SSBs, participants reported consuming
less SSBs after a workplace sales ban and a reduction in waist
circumference and sagittal diameter but no change in bodymass
index or insulin sensitivity. Those randomized to receive a brief
motivational intervention had greater improvements.
Meaning Aworkplace sugar-sweetened beverage sales ban,
especially if combined with a brief intervention, may be a feasible
and effective way to improve employee health.
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214 employees who met all inclusion criteria, including avail-
ability for a morning phlebotomy appointment. Of the 349 in-
dividualsdeemedeligible after screening, 135declinedand214
(61.3% of the eligible sample) were enrolled.
Attheendofthebaselineassessment,werandomlyassigned
109 participants to receive a brief motivational intervention
targeting reductions in SSB intake and 105participants to be in
acontrol groupthatdidnot receive the intervention.Aresearch
assistant (A.H.)performedtherandomizationusingacomputer-
generated program that used block randomization to random-
ize participants to control (0) or intervention (1) (details in the
trial protocol in Supplement 1).
Participants randomized to the brief motivational inter-
vention immediatelymet with the health educator for a brief
(approximately 15 minutes) motivational interview using an
adapted version of a standard alcohol brief intervention.14
Health educators trained in motivational interviewing de-
scribed the amount of sugar ingested given the daily amount
of SSBs consumed (using sugar cubes in a cup), gave personal
guidance on risk and reducing sugar intake, helped the par-
ticipant set a health goal associatedwith SSB intake (trial pro-
tocol in Supplement 1), and provided educational materials.
Health educators made brief (approximately 5 minutes)
“booster” telephone calls to revisit goals at 1 week after the
baseline visit, 1 month after implementation of the SSB sales
ban, and 6months after implementation of the SSB sales ban
(trial protocol in Supplement 1).
The(maskedtocondition) researchstaff reassessedthepar-
ticipants 10months after baseline, fromMay 30 toAugust 30,
2016. A total of 202 of 214 study participants completed both
survey assessments (retention rate, 94.4%; Figure 1). Partici-
pantswho completedboth survey assessments and clinic vis-
its were compensated $125 ($50 for the baseline visit and $75
for the follow-up).
Measures
All participants were assessed in the clinic at baseline and af-
ter 10 months using identical instruments and procedures.
Sugar-sweetened beverage consumption was assessed sepa-
rately via surveys at baseline and 6 and 12months. Outcomes
included changes in SSB intake, insulin sensitivity as mea-
sured by Homeostatic Model Assessment of Insulin Resis-
tance (HOMA-IR) (primary outcome),15 and abdominal adi-
posity asmeasuredbywaist to hip ratio,waist circumference,
and sagittal diameter.
SurveyMeasures
Survey measures include sociodemographic questions (in-
cluding race/ethnicity, job class, age, sex, place of birth, and
primary language spoken at home) and beverage intake using
a 15-item beverage intake questionnaire.6 This standardized
instrument asks about the type, frequency, and amount
(ounces) of specific types of beverages consumedon a typical
day.Daily intakewascalculated for eachbeverage typebymul-
tiplying the frequency of intake and serving size. All regular
or nondiet sodas, “fruit” drinks, sports or energy drinks, and
sweetened coffee or tea drinks were counted as SSBs.
Anthropometric Measures
Anthropometric measurements included weight measure-
mentusingadigital scalewith shoesoff andheightusinga sta-
diometer. In addition, trainedassistants (includingA.H.)mea-
suredwaist andhipcircumferencesusingacloth tapemeasure
and sagittal diameterusing ananthropometermeasuring stick
device, twice each with means taken.
Biomarkers
Participants had 30 mL of blood drawn while they were in a
fasting state; samples were immediately processed into se-
rum, plasma, and whole blood aliquots, and frozen at –80°C
forbatchassayby the research laboratoryofPeterHavel,DVM,
University ofCalifornia,Davis. Fastingblood sampleswere as-
sayed for glucose, insulin, and exploratory biomarkers, in-
cluding hemoglobin A1c, lipid profile (including cholesterol,
low-density lipoprotein cholesterol, high-density lipoprotein
cholesterol, triglycerides, apolipoproteinA1, and apolipopro-
tein B), uric acid, γ-glutamyl transpeptidase, and alanine
aminotransferase.
Figure 1. Intervention Enrollment Flowchart
699 Individuals screened for eligibility
based on reported SSB intake
109 In intervention group 105 In control group
109 Completed baseline 105 Completed baseline
103 Completed follow-up 99 Completed follow-up
214 Eligible and randomized
485 Excluded
135 Eligible but declined
58 Schedule did not allow
participation
112 With insufficient SSB intake
on more detailed assessment
88 Did not work at study
campus
30 With health conditions (eg,
diabetes, cancer, or
pregnancy)
62 Other (eg, not fluent in
English or phobia of needles)
6 Refused to
participate or
were lost after
baseline
6 Refused to
participate or
were lost after
baseline
Themost common reasons for ineligibility were insufficient sugar-sweetened
beverage (SSB) intake and working at a different campus and inability to make a
morning blood draw; themost common reason for declining to participate was
being too busy (details in trial protocol in Supplement 1). Twelve participants
were lost to follow-up because they had left University of California
San Francisco for other jobs or moved (n = 5), became pregnant (n = 5), or
developed a condition that made them ineligible (n = 2). Of the 202
participants total who completed the follow-up survey, 184 of them also
completed the in-person assessment/blood draw. The reasons that 18 did
not complete the blood draw included illness/schedule conflicts (n = 13)
or lack of interest (n = 5).
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Statistical Analysis
Dataweredouble checked (trial protocol in Supplement 1) and
all analyseswereperformedonaper protocol basis usingdata
from the whole sample. Secondary analysis parsed partici-
pants with a baseline body mass index (BMI) (calculated
as weight in kilograms divided by height in meters squared)
of below 25 (lean; n = 48), vs 25 or above (overweight or
obese; n = 137). Planned analyses, per registration with
ClinicalTrials.gov (NCT02585336), examined the following 3
outcomes:HOMA-IR (primary), SSB intake (secondary), andab-
dominal adiposity (secondary). Analyses examined: (1) the as-
sociation of the SSB sales ban with self-reported SSB intake,
abdominal adiposity, and HOMA-IR; (2) any additional asso-
ciation of the brief intervention with SSB intake; and (3) the
associationbetweenSSB intake and changes inHOMA-IR (pri-
mary analysis). All other biomarkerswere considered explor-
atoryoutcomes.Weused2-sidedhypothesis tests,withP < .05
considered statistically significant for the primary analyses.
We first analyzedchangescores indailySSB intake, adipos-
ity,andHOMA-IR,atbaselineandthefollow-ups.Weusedpaired
t tests to examinewhether differences at each timepointwere
significantlydifferent fromzero, across the sampleandbyBMI
group (Table). In addition to these unadjusted analyses, mul-
tiple regressions assessed whether changes in SSB intake at 6
monthswereassociatedwithchanges inHOMA-IRandabdomi-
nal adiposity, controlling for covariates such as sex, BMI, and
baseline levels of the outcomes (eTable 2 in Supplement 2).
A final set of analyses tested for any added associations of
thebrief interventionusing t testsandmultiple regressionmod-
els incorporating the covariates above. In secondary analy-
ses, we explored whether the intervention was more effec-
tive for thosewithhighBMIby testing an interactionbetween
BMI and intervention group (eTable 3 in Supplement 2) and
changes inexploratorybiomarkersusing t testsofchangescores
(eTable4 inSupplement 2). Thedatawere analyzed from2018
to 2019.
Results
Themean (SD) age of study participants was 41.2 (11.0) years
(range, 18-68years) at baseline (eTable 1 inSupplement2). The
sample included 124 women and 90 men, with broad ethnic
representation:58Asian-American individuals (27.1%),32black
individuals (15.0%), 42 Latino individuals (19.6%), 47 white
individuals (22.0%), and 35 individuals of unknown or
unstatedrace/ethnicity (16.4%).Studyparticipantsworkedpre-
dominantly in service and technical occupations (77 [36.0%]),
with25 individuals (11.7%) inmedical and/oracademic jobclas-
sifications.A total of24of83men (28.9%)and55of 117women
(47.0%) were obese (BMI ≥30).
The Table reports outcomes (SSB intake, anthropomet-
rics, and HOMA-IR) for the full sample and for lean and over-
weight and obese study participants, before and after the SSB
salesban,withPvalues for t tests comparingvaluesbefore and
after the sales ban for each group. Employees reported a re-
ducedSSB intake fromamean (SD) of 1050.0 (804.0)mL (35.0
[26.8] fl oz) at baseline to 540.0 (591.0) mL (18.0 [19.7] fl oz)
per day 6 months after the sales ban, a reduction of 48.6%
(510.0 mL [17.0 fl oz]; t = 8.24; P < .001). These reductions
remained stable at 12 months across groups (Figure 2).
ReductionsinSSBconsumptionwerestatisticallysignificant
inboth the leanandoverweightandobesegroups (Table).Low-
BMIparticipants reported reductionsof 186.0mL(6.2 fl oz)per
day(P = .05),whereashigh-BMIparticipantsreportedreductions
of 588.0mL (19.6 fl oz) per day (P < .001); a greater changewas
seen in the high-BMI group (t = –2.86; P = .01).
Therewas nomean change inHOMA-IR or BMI, although
there were reductions in 2 of 3 measures of abdominal adi-
posity: mean (SE) waist circumference decreased by 2.1
(2.8) cm (t = 5.61;P < .001) and sagittal diameter decreasedby
0.4 (2.2) cm (t = 2.36;P = .01). Bodymass index andwaist cir-
cumference, althoughhighly correlated (r = 0.91 at baseline),
Table. SSB Intake and Cardiometabolic Outcomes at Baseline and Post-SSB Sales Ban, by BMI
Outcome
Full Sample Lean (BMI <25) Overweight or Obese (BMI >25)
No.
Mean (SD)
P Value No.
Mean (SD)
P Value No.
Mean (SD)
P ValueBaseline Follow-up Baseline Follow-up Baseline Follow-up
Daily SSB intake, mLa
6 mo After
sales ban
195 1050.0
(804.0)
540.0
(591.0)
<.001 47 870.0
(666.0)
687.0
(699.0)
.05 136 1083.0
(828.0)
495.0
(522.0)
<.001
12 mo After
sales ban
181 1053.0
(804.0)
522.0
(642.0)
<.001 45 834.0
(609.0)
528.0
(672.0)
.002 128 1116.0
(840.0)
531.0
(645.0)
<.001
Adiposity (10 mo
after sales ban)
BMI 171 29.4
(6.5)
29.5
(6.5)
.38 48 22.5
(2.3)
22.7
(2.4)
.04 123 32.1
(5.5)
32.1
(5.5)
.45
Waist
circumference, cm
170 98.7
(16.7)
96.5
(15.8)
<.001 48 81.6
(7.7)
80.4
(7.6)
.03 122 105.4
(14.3)
102.8
(13.5)
<.001
Sagittal
diameter, cm
171 24.7
(5.6)
24.3
(5.6)
.01 49 19.4
(2.6)
19.4
(3.0)
.47 122 26.9
(5.0)
26.3
(5.1)
<.001
Waist to hip ratio 170 0.94
(0.09)
0.94
(0.10)
.28 48 0.88
(0.09)
0.88
(0.08)
.45 122 0.96
(0.09)
0.96
(0.09)
.21
HOMA-IR (10 mo
after sales ban)
180 4.7
(3.4)
4.8
(3.7)
.33 49 3.0
(1.3)
3.0
(1.3)
.43 120 5.3
(3.8)
5.2
(3.1)
.30
Abbreviations: BMI, bodymass index (calculated as weight in kilograms divided
by height in meters squared); HOMA-IR, Homeostatic Model Assessment of
Insulin Resistance; SSB, sugar-sweetened beverage.
a To convert milliliters to fluid ounces, divide by 30.
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did not consistently change together. Approximately half the
sample lost weight and half gained weight, leading to no sig-
nificant change. Incontrast, 117of 170participants (68.8%) lost
waist girth, leading to a mean (SE) loss of 2.1 (2.8) cm; these
study participants tended to be the oneswho also lost weight
(75 of 117 [64.1%] lost weight).
Wenextconductedcorrelationsandregressions for thepri-
maryanalysisofSSB intakeandHOMA-IR.Pearsoncorrelations
showedthatchange inSSB intakewasassociatedwithchange in
HOMA-IR (r = 0.16;P = .03) and insulin (r = 0.16;P = .04),with
more pronounced associations in exploratory analyses of the
high-BMI group (r = 0.24; P = .01 for HOMA-IR; and r = 0.21;
P = .03forinsulin). Inmultivariateregressionscontrollingforsex,
baselineBMI, andbaselineHOMA-IR, reductions in SSB intake
were still associatedwith lowerHOMA-IRafter exposure to the
intervention (β = 0.02; P = .02) (eTable 2 in Supplement 2).
Change in SSB intake was not associated with change in waist
circumference (r = −0.01; P = .94; in multivariate regression,
β = −0.13; P = .07) (eTable 2 in Supplement 2).
Brief Motivational Intervention
Employees exposed to the SSB sales ban plus the brief inter-
vention reduced mean (SD) daily SSB intake by 762.0
(84.0) mL (25.4 [2.8] fl oz), vs a reduction of 246.0 (84.0) mL
(8.2 [2.8] fl oz) among thoseexposed to theSSBsalesbanalone
(t = −4.37; P < .001). This added association of the interven-
tionwith SSB intakewas significantly greater in the high-BMI
group (n = 136) (840-mL [28–fl oz] vs 300-mL [10–fl oz] re-
duction; P < .001) and not significant in the low-BMI group
(n = 47) (69.0 mL [2.3 fl oz] vs 327.0 mL [10.9 fl oz]; P = .27),
althoughthisdifferencecouldbeowing to lowstatisticalpower
in the latter. Figure 3 shows the total reduction for low-BMI
and high-BMI groups, including the additional reduction re-
sulting from assignment to the brief intervention.
Multivariate regression analysis found that those ex-
posed to the SSB sales ban plus the brief intervention experi-
enced an additional 369.0-mL (12.3–fl oz) decline in daily SSB
intake (F4,177 = 71.37;P < .001), explaining6%of the total vari-
ance (eTable 3 in Supplement 2). The interaction termdid not
reach statistical significance, but given the greater reduction
in SSB intake observed in those with a higher BMI, this find-
ing warrants additional investigation.
Exploratory Biomarkers
Across the sample, uric acid andhigh-density lipoprotein cho-
lesterol levels improved over time, but total cholesterol and
low-density lipoprotein cholesterol levels also increased in the
lean group (BMI <25) (eTable 4 in Supplement 2). Compari-
sons by intervention group found that those in the lean group
experienced increases in lipids, regardless of condition.How-
ever, those with overweight and obesity (BMI ≥25) who were
assigned to the brief intervention showed statistically signifi-
cant improvements in lipids (total cholesterol, low-density
lipoprotein cholesterol, and apolipoprotein B levels) com-
pared with those exposed to the sales ban only (eTable 5 in
Supplement 2). Exploratory analyses found small associa-
tions between changes in SSB intake and changes in total cho-
lesterol (r = 0.22;P = .004), but no associationwith triglycer-
ides (r = 0.14; P = .08), high-density lipoprotein cholesterol
(r = 0.13;P = .10), low-density lipoproteincholesterol (r = 0.15;
P = .06), apolipoprotein B (r = 0.11; P = .17), or liver enzymes
(alanine transaminase: r = 0.08; P = .31).
Discussion
There is substantial literatureontobaccoandalcohol salesbans
demonstrating reduced intake and improved health
Figure 2. Mean Sugar-Sweetened Beverage (SSB) Intake
Under an SSB Sales Ban Intervention
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less. BMI indicates bodymass index (calculated as weight in kilograms divided
by height in meters squared). Vertical lines indicate 95% CIs. To convert
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Figure 3. Mean Reduction in Daily Sugar-Sweetened Beverage (SSB)
Consumption Attributed to Sales Ban Only vs Added Association
of a Brief Intervention 12Months After Baseline
900
750
600
450
150
300
0
M
ea
n 
Re
du
ct
io
n 
in
 D
ai
ly
 S
SB
 C
on
su
m
ed
, m
L
Full Sample BMI <25 BMI ≥25
Brief intervention
Sales ban
Light blue bars show the self-reported reduction in SSB intake in those exposed
to the sales ban only, and dark blue bars show the additional reduction reported
by those exposed to the brief intervention plus sales ban. The total height of the
bar shows the total amount reduced for those in the brief intervention plus
sales ban. The pattern for change in SSB at 12 months is similar, as shown in
eTable 5 in Supplement 2. BMI indicates bodymass index (calculated as weight
in kilograms divided by height in meters squared). To convert milliliters to fluid
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outcomes.16 Workplace bans on tobacco sales have led to re-
ductions in tobaccouseaswell asnormative shifts in thepopu-
larity of smoking.17,18 Despite the increased use of workplace
SSB sales bans, to our knowledge, there have been no prior
peer-reviewed studies documenting the association of such
sales banswithhealth. School-based SSB sales bans have suc-
cessfully reduced the in-school purchasing of SSBs, although
student intakeof SSBsbrought fromhomeandconsumedout-
side of school may reduce these positive associations.19,20
There is growing interest inworkplace SSB sales bans as a
nongovernmental strategy for reducing SSB intake, thusmiti-
gatingassociated cardiometabolicdisease risks. This studyex-
aminedwhether aworkplaceSSBsalesbancoulddecreaseem-
ployee SSB intake, and whether such decreases would result
in improved cardiometabolic health.
As hypothesized, aworkplace SSB sales banwas followed
bya significantdecrease in employee-reportedSSB intake.Af-
ter the sales ban’s implementation, frequent SSB consumers
(≥360mL [≥12 fl oz] of SSBs per day) reported amean decline
in consumption of 510mL [17 fl oz], with significantly greater
reductions in SSB intake among employees with overweight
and obesity. Decreased SSB intake was associated with small
beneficial changes in insulin resistance (primary outcome),
alongwith ameaningful decrease inwaist circumference (sec-
ondary outcome). Population-based studies have found that
sugar intake is associated with abdominal adiposity, HOMA-
IR,and lipid levels.21Anexperimental studycontrolling for food
intake showed that reductions in added sugar are associated
with improvements invisceral fat,HOMA-IR,and lipid levels.22
Consistentwiththese findings,wefoundassociationsover time
between reductions in SSB intake and reductions inHOMA-IR
(ourprimaryoutcome), and, inexploratoryanalyses,with total
cholesterol but not other lipid levels.
At theoutset,weexpectedchanges inwaist circumference
butnotBMI,whichwasconfirmed,withapproximatelyhalf the
sample losingweightandhalf gainingweight.Meanwhile,69%
lostwaist girth; these study participants tended to be the ones
whoalso lostweight.Bodymass indexandwaist circumference
represent fat depots that are differentially regulated, with ab-
dominal adiposity specifically linked tomyocardial infarctions
inpopulation-attributable risks.23 Short-term isocaloric reduc-
tions in sugar consumption have been shown to lead to reduc-
tions in lipids24 andHOMA-IR.22 In this controlled feeding trial
thatsubstitutedstarchforsugarwhilekeepingtotalcaloriescon-
stant, researchers founda22%reduction in liver fat and7%re-
duction in visceral fat, with essentially no change in BMI.22
This study added a randomized clinical trial of a brief em-
ployer-based motivational intervention. Employees who re-
ceived thebrief interventionas anadjunct to theSSB sales ban
reported the largest decreases in SSB intake and experienced
the greatest benefits for cardiometabolic health risk. Employ-
ers have efficiently and effectively implemented brief inter-
ventions to address employee alcohol intake formanyyears,25
andsimilar approachescouldbeused to targetSSBs.This study
suggests that combiningchanges in the foodenvironmentwith
atargeted interventioncanbolsterhealthbenefitsbeyondthose
achievedbyaworkplace salesbanalone.Future studies should
examine longer-termassociations ofworkplace SSB interven-
tions and assess the potential cost savings to employers, who
currently face rising employee health care costs owing to
metabolic syndrome (obesity, type 2 diabetes, heart disease,
and fatty liver disease).26
Limitations
Thisstudyhassomelimitations.Thisadditionalrandomizedtrial
controlled for the SSB sales ban plus brief intervention group
butnot for thesalesbanonlygroup.Duetotimeconstraintsper-
taining toUCSF’s implementationof theSSBsalesban,wewere
unable to enroll a contemporaneous external control institu-
tion without an SSB sales ban. However, exploratory analyses
foundmorepronounced associations in overweight andobese
employees and in the controlled brief intervention condition,
suggesting that the changes observed in this studymay not be
completely attributable to secular factors.
We also note limitations in the accuracy of self-reported
SSB intake. Although it is possible that the observed declines
in SSB intake are indicative of regression to the mean, the 2
follow-up time points at 6 and 12 months are both lower and
are correlatedwith eachother (r = 0.60;P < .001), suggesting
a stable change. Although social desirability bias could ex-
plain reporting lower values, the correlation of SSB changes
with expected changes in blood-based biomarkers (HOMA-IR
and lipid levels) suggests true improvement for those who
reported lowering their SSB intake. Observed declines in SSB
consumptionareunlikelyduetoseasonalchanges,as theywere
sustained for 12 months (Figure 2).
It appears that future research should use more rigorous
dietary assessments to more precisely determine the associa-
tion betweenhealth improvements and changes or reductions
inall sourcesofsugar intake.Finally, thegeneralizabilityof these
findings is limited to an urban environment of frequent SSB
drinkers and a disproportionately ethnicminority sample.
Conclusions and Public Health Implications
As rates of cardiometabolic diseases continue to rise, private
employers are likely to facegreaterproductivity losses andpri-
vatehealthexpenditures.The resultsof this studysuggest that
workplace SSB sales bans, if widely adopted, could add an-
other layer of efficacy to existing SSB reduction strategies. At
the societal level, private sector–driven change throughwork-
place sales bans seems to offer a strategy that complements
existinggovernmental reformefforts.Althougheffective, gov-
ernmental reform policies, such as SSB taxation and warning
labels, face significant political obstacles that private-sector
sales bans do not.
Contractual arrangementswith beverage companiesmay
pose obstacles to implementingworkplace SSB sales bans, al-
thoughbeveragecompaniesare increasingly reformulatingand
diversifyingproduct lines toofferhealthieralternatives toSSBs.
Somepublic andnonprofit sector employers, includingmany
schools and universities, face challenges resulting from bev-
erage company subsidies of sports teamsandother activities—
so-called pouring rights contracts—that require on-campus
marketing,promotion, andsales.Finally, someemployersmay
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face challenges in aworkplace culture inwhich SSB sales bans
are perceived as paternalistic. Despite these barriers, there is
a growing movement to ban the workplace sale of SSBs, par-
ticularly in the health sector, where this strategy proves con-
sistent with the organizational mission. Our data appear to
support the health benefits of this approach.
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